Clinical outcomes after switching from omalizumab to anti-IL-5/IL-5R biologics in severe asthma: a retrospective cohort study

Key Points

• Switching from omalizumab to IL-5 biologics improves clinical outcomes in severe asthma patients.
• Key predictors for treatment change were identified based on baseline clinical parameters.
• Retrospective cohort analysis evaluated the effectiveness of changing biological therapies.
• Findings suggest potential benefits of tailored biologic treatment strategies in severe asthma cases.